Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Alvotech said it generated about $600 million of revenue and roughly $140 million of EBITDA last year, and guided to $650 million-$700 million of revenue and $180 million-$200 million of EBITDA this year. The company also highlighted U.S. launches of biosimilar Humira in 2024 and Stelara in February 2025, with additional biosimilar filings for Simponi, Eylea, Prolia and Xgeva. The update is constructive, but it is largely a conference discussion rather than a new catalyst.

Analysis

Alvotech is transitioning from a one-product commercial story to a portfolio monetization story, and that matters more than near-term headline growth. The key second-order effect is manufacturing leverage: once a biosimilar platform is validated, incremental launches tend to carry materially higher contribution margins than the first wave because fixed plant, QA, and regulatory overhead are already in place. That supports the idea that EBITDA can inflect faster than revenue over the next 12-18 months, which is the real bull case here.

The competitive dynamic is also improving because biosimilar pricing pressure is most intense at launch and then moderates as contracting resets. If Alvotech can continue to add approved assets, it can become a preferred supplier to large distributors and PBMs that want multi-asset biosimilar coverage, which increases switching costs for channel partners and reduces the probability of a single-product compression event. The flip side is that this is still a trust-and-execution trade: any manufacturing quality issue, tender loss, or delayed approval would hit both growth and multiple simultaneously.

The market may be underestimating how much of the story is about optionality beyond the current commercial base. Each additional filing expands the probability-weighted pipeline value, but the stock likely won’t fully re-rate until the company proves it can convert approvals into durable net pricing and cash generation rather than just top-line growth. Near term, the main catalyst path is successive launch/read-throughs over the next 2-3 quarters; the main bear case is that biosimilar competition becomes a race to the bottom faster than operating leverage can offset.

Contrarian view: the consensus may be too focused on reported revenue guidance and not enough on quality of earnings. If the business is now crossing into a regime where EBITDA growth outpaces sales growth, the multiple should be judged more like an industrial platform with recurring launch optionality than a single-asset biotech. The risk is that investors pay for that re-rating before the cash conversion and free cash flow actually show up, creating a short-window opportunity for patience.

Key Decisions for Investors

• Long ALVO on pullbacks over the next 1-2 weeks; target a 6-12 month hold into the next launch/readout cycle. Risk/reward is attractive if EBITDA continues to compound faster than revenue, but size modestly because execution risk remains binary around manufacturing and payer access.
• Pair trade: long ALVO / short a mature biosimilar peer with limited pipeline optionality over 3-6 months. The thesis is that ALVO’s multi-launch cadence should create a higher growth duration than a single-asset or slow-turning competitor, while keeping sector beta hedged.
• Buy ALVO call spreads 3-6 months out to express upside on re-rating without taking full equity drawdown risk. Best setup is a catalyst-driven move if the market starts capitalizing the earnings power of successive biosimilar launches.
• If ALVO rallies sharply on guidance optimism, fade into strength with a partial hedge until free cash flow conversion is demonstrated. The stock can overshoot on headline EBITDA improvement before the market is convinced the margin structure is durable.